Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Inclusion Criteria: * Written informed consent has been obtained. * Adults 18 years of age or older with a life expectancy of at least 3 months. * Histologically confirmed castration-resistant prostate cancer (CRPC). Patient must have demonstrated a rising PSA level above the androgen-deprivation therapy (ADT) nadir, on at least two determinations four weeks or more apart. ADT is defined as treatment with a Luteinizing-hormone-releasing hormone (LHRH) agonist or orchiectomy. * Treatment with only one prior chemotherapy regimen, which must contain docetaxel as a single agent or in combination with other agents. Patients may be intolerant of, or resistant to, the cytotoxic drug combination. * Patients on ADT must be willing to continue ADT for the duration of their participation in this protocol. ADT cannot be initiated, and ADT dose/agents may not be changed during the study. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Adequate hematologic function (absolute neutrophil count \[ANC\] ≥ 1,500 cells/μL; hemoglobin ≥ 8 g/dL, platelets ≥ 100,000/μL). * Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min). * Adequate hepatic function (bilirubin ≤ 1.0 x upper limit of normal \[ULN\], alanine aminotransferase \[ALT\] ≤ 1.5 x ULN, aspartate aminotransferase \[AST\] ≤ 1.5 x ULN). * Prothrombin time (PT) / international normalized ratio (INR) ≤ 1.5 × ULN. * Activated partial thromboplastin (aPTT) time ≤ 1.5 × ULN. * Prostate-specific antigen (PSA) level of at least 2 ng/mL. * New York Heart Association classification I or II. * All patients of reproductive potential must agree to use an approved form of contraception (as determined by the investigator). Exclusion Criteria: * Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia). * Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism); central venous catheter-related thrombosis \> 6 months before Screening is allowed. * Ongoing therapy with oral or parenteral anticoagulants; patients on low-dose anticoagulants to maintain patency of central venous catheters are eligible. * Grade 2 or higher peripheral neuropathy (e.g., numbness, tingling, and/or pain in distal extremities). * Radiotherapy (teletherapy or brachytherapy) , chemotherapy or estrogen agonist within 28 days before Study Day 1. * Systemic radiotherapy (Sm-153, Sr-89) within 56 days before study day 1. * Symptomatic or clinically active brain metastases. * Major surgery within 28 days of Study Day 1. * Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease). * Any history of cerebrovascular accident, or transient ischemic attack at any time, or history of symptomatic coronary artery disease \< 6 months before screening. * A history of any condition requiring anti-platelet therapy (eg, phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), with the exception of general cardiovascular prophylaxis with aspirin (≤ 325 mg/day). * Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture). * Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis. * Contraindication to intravenous (IV) contrast media.